NCT02197897View on ClinicalTrials.gov

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

September 12, 2017

Study Completion Date

June 28, 2019

Conditions
Bladder Cancer
Interventions
DRUG

Tamoxifen Citrate

Single-center, two-stage phase-II clinical trial (Simon design)

Trial Locations (2)

77030

Baylor College of Medicine, Houston

Harris Health System, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Baylor College of Medicine

OTHER

NCT02197897 - Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors | Biotech Hunter | Biotech Hunter